What is Zacks Research’s Estimate for AXSM FY2027 Earnings?

Axsome Therapeutics, Inc. (NASDAQ:AXSM) – Zacks Research issued their FY2027 earnings estimates for shares of Axsome Therapeutics in a report issued on Tuesday, March 11th. Zacks Research analyst R. Department forecasts that the company will earn $5.75 per share for the year. The consensus estimate for Axsome Therapeutics’ current full-year earnings is ($2.79) per share.

AXSM has been the subject of several other research reports. HC Wainwright restated a “buy” rating and issued a $200.00 target price on shares of Axsome Therapeutics in a report on Thursday, March 6th. Wells Fargo & Company upped their target price on shares of Axsome Therapeutics from $140.00 to $160.00 and gave the company an “overweight” rating in a report on Wednesday, February 12th. Royal Bank of Canada upped their target price on shares of Axsome Therapeutics from $143.00 to $192.00 and gave the company an “outperform” rating in a report on Wednesday, February 19th. Truist Financial upped their target price on shares of Axsome Therapeutics from $190.00 to $200.00 and gave the company a “buy” rating in a report on Wednesday, February 19th. Finally, Morgan Stanley increased their price target on shares of Axsome Therapeutics from $125.00 to $190.00 and gave the stock an “overweight” rating in a research note on Thursday, February 27th. One research analyst has rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $167.36.

Axsome Therapeutics Trading Up 1.8 %

Shares of NASDAQ:AXSM opened at $121.65 on Thursday. The company’s 50 day moving average is $111.54 and its two-hundred day moving average is $98.58. Axsome Therapeutics has a 52 week low of $64.11 and a 52 week high of $139.13. The company has a current ratio of 2.11, a quick ratio of 2.04 and a debt-to-equity ratio of 3.22. The company has a market cap of $5.93 billion, a PE ratio of -20.31 and a beta of 1.00.

Axsome Therapeutics (NASDAQ:AXSM) last announced its quarterly earnings data on Tuesday, February 18th. The company reported ($0.96) EPS for the quarter, beating analysts’ consensus estimates of ($0.97) by $0.01. Axsome Therapeutics had a negative net margin of 74.47% and a negative return on equity of 223.51%. The company had revenue of $118.77 million for the quarter, compared to the consensus estimate of $117.83 million.

Insider Transactions at Axsome Therapeutics

In other news, CFO Nick Pizzie sold 3,000 shares of the stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $131.07, for a total value of $393,210.00. Following the completion of the transaction, the chief financial officer now owns 42,187 shares in the company, valued at $5,529,450.09. This trade represents a 6.64 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 22.40% of the company’s stock.

Hedge Funds Weigh In On Axsome Therapeutics

A number of large investors have recently made changes to their positions in the stock. BVF Inc. IL increased its holdings in shares of Axsome Therapeutics by 32.7% in the 4th quarter. BVF Inc. IL now owns 1,388,064 shares of the company’s stock valued at $117,444,000 after purchasing an additional 342,064 shares in the last quarter. FMR LLC increased its holdings in shares of Axsome Therapeutics by 20.6% in the 3rd quarter. FMR LLC now owns 1,088,087 shares of the company’s stock valued at $97,786,000 after purchasing an additional 185,951 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of Axsome Therapeutics by 0.4% in the 4th quarter. Geode Capital Management LLC now owns 912,538 shares of the company’s stock valued at $77,228,000 after purchasing an additional 4,079 shares in the last quarter. Wellington Management Group LLP increased its holdings in Axsome Therapeutics by 1.1% during the 3rd quarter. Wellington Management Group LLP now owns 742,745 shares of the company’s stock valued at $66,750,000 after acquiring an additional 8,125 shares in the last quarter. Finally, Invesco Ltd. increased its holdings in Axsome Therapeutics by 10.8% during the 4th quarter. Invesco Ltd. now owns 692,464 shares of the company’s stock valued at $58,589,000 after acquiring an additional 67,285 shares in the last quarter. Hedge funds and other institutional investors own 81.49% of the company’s stock.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.